Skip to content

Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells

Autologous Adipose-derived Mesenchymal Stem Cells in the Treatment of Tendon Disease: a Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03279796
Enrollment
200
Registered
2017-09-12
Start date
2018-10-01
Completion date
2021-12-31
Last updated
2018-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lateral Epicondylitis, Rotator Cuff Tear

Keywords

Adipose-drived mesenchymal stem cells, Rotator cuff injury, Lateral Epicondylitis, Randomized controlled trials

Brief summary

This study was a single-center, randomized, single-blind clinical trial. We plan to include 100 patients who met exclusion criteria of rotator cuff and lateral epicondylosis (tennis elbow) respectively by MRT or ultrasonography. The patients will be randomly divided into two groups. Adipose mesenchymal stem cells will be isolated from adipose tissue, cultured and then transplanted back to the tendon injury site by multiple point injection. 1\*10\^6 cells as an unit. Patients in the experiment group will be injected into an unit of adipose mesenchymal stem cells (1\*10\^6/10kg) while the control group received the same dose compound betamethasone injection. Follow up visit for all patients will occur at 1,3,6 and 12 months after the first injection. Clinical quantitative assessment will measure by the visual analogue scale(VAS). The secondary outcomes are the constant-murley score(CMS) and the rating scale of the American shoulder and elbow surgeons(ASES) and the disability of arm shoulder and hand(DASH). The objective evaluation methods is that the examination of MRI or ultrasound were accomplished before the first injection and at 6 and 12 months afterwards.

Detailed description

All injection will be done under ultrasound guidance.

Interventions

BIOLOGICALAutologous adipose-derived MSCs

The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 \^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.

1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.

Sponsors

Zhejiang Xingyue Biotechnology Co., Ltd.
CollaboratorINDUSTRY
Second Affiliated Hospital, School of Medicine, Zhejiang University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

1. clinically diagnosed as rotator cuff tear or lateral epicondylitis (tennis elbow); 2. symptom duration is over 3 months, non-steroidal drug treatment , rehabilitation treatment and other conservative treatment is invalid; 3. patient that can understand the clinical trials and signed the informed consent.

Exclusion criteria

1. patient that underwent other injection treatment within 6 weeks 2. some associated diseases (such as arthritis, synovitis, entrapment of related nerve, radiculopathy to the target lesion, generalized pain syndrome, rheumatoid arthritis, pregnancy, impaired sensibility, paralysis, history of allergic or hypersensitive reaction to bovine-derived proteins or fibrin glue) 3. patient that enrolled other clinical trials within 3 months 4. history of drug/alcohol addiction, habitual smoker

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeksBaseline, 3 weeks, 6 weeks, 12 weeks after interventionPain on activity will be evaluated by VAS

Secondary

MeasureTime frameDescription
Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,Baseline, 3 weeks, 6 weeks, 12 weeks after interventionFunctional score of the shoulder
American Shoulder and Elbow Surgeons (ASES) Shoulder ScoreBaseline, 3 weeks, 6 weeks, 12 weeks after interventionFunctional score of the shoulder
The Disabilities of the Arm, Shoulder and Hand(DASH) ScoreBaseline, 3 weeks, 6 weeks, 12 weeks after interventionFunctional score of the shoulder
Adverse eventsFrom baseline through study completion, an average of 1 yearAdverse events to evaluate the safety

Countries

China

Contacts

Primary ContactWeiliang Shen, Doctor
wlshen@zju.edu.cn+86-13757101563

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026